Zenas BioPharma Raises Capital via Notes and Equity Offering

Zenas BioPharma, Inc. ( (ZBIO) ) has issued an update.

On March 31, 2026, Zenas BioPharma completed a $200 million public offering of 2.50% Convertible Senior Notes due 2032 and a concurrent equity offering of 5 million common shares at $20 each, raising net proceeds of about $193.7 million and $93.7 million, respectively. The convertible notes, which feature multiple conversion triggers, redemption and repurchase rights, and customary default provisions, could result in issuance of up to 11.5 million additional shares, potentially diluting existing shareholders but strengthening the company’s balance sheet.

Zenas plans to deploy the combined proceeds to fund the planned U.S. commercial launch of obexelimab for IgG4-related disease if approved, advance Phase 3 trials of orelabrutinib in progressive multiple sclerosis, and support Phase 1/2 development of ZB021, as well as general corporate purposes. The twin financings come against a backdrop of substantial historical losses and going-concern risks, underscoring both the capital intensity of the company’s late-stage pipeline and the execution risk investors face as Zenas moves toward potential commercialization and broader clinical development.

The most recent analyst rating on (ZBIO) stock is a Hold with a $18.00 price target. To see the full list of analyst forecasts on Zenas BioPharma, Inc. stock, see the ZBIO Stock Forecast page.

Spark’s Take on ZBIO Stock

According to Spark, TipRanks’ AI Analyst, ZBIO is a Neutral.

The score is driven primarily by weak financial performance (large losses, declining revenue, and heavy cash burn) and bearish technicals (price below key moving averages and negative MACD). These are partially offset by a low-debt balance sheet and a strong positive corporate event (successful Phase 3 data with stated plans for near-term regulatory filings).

To see Spark’s full report on ZBIO stock, click here.

More about Zenas BioPharma, Inc.

Zenas BioPharma, Inc. is a biopharmaceutical company focused on developing and commercializing product candidates for immune-mediated and other serious diseases. Its pipeline includes obexelimab for IgG4-related disease, orelabrutinib for progressive multiple sclerosis, and ZB021, targeting U.S. and global specialty markets where there is significant unmet medical need.

Average Trading Volume: 970,938

Technical Sentiment Signal: Sell

Current Market Cap: $1.05B

For detailed information about ZBIO stock, go to TipRanks’ Stock Analysis page.